Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept Phase III Trial in Pathologic Myopia Choroidal Neovascularization
CTR20131260Phase 3Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Mar 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in myopic choroidal neovascularisation (mCNV), sponsored by Chengdu Kanghong Pharmaceutical Group. Started Mar 2014; status: completed.
02
Drugs
conbercept
03
Conditions
myopic choroidal neovascularisation (mCNV)
Beyond the preview
Go deeper on CTR20131260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131260.